Can Rebif Cause Depression?
Understanding Clinical Trials
Clinical trials are designed to factor out many possible variables in order to measure the effectiveness and side effects of medications.
During a study, some people are given the actual medication, while others are given a placebo, which looks like the actual medication but does not contain any of the active ingredients. In most studies, the people (and sometimes the healthcare providers) are "blinded," which means that they do not know if they are taking the real medication or the placebo. Since Rebif is given by injection, the placebo in Rebif studies was also an injection, although it contained no active ingredient.
Side effects occurred in people who were taking the medicine and in people who were taking a placebo. By studying both groups, it becomes easier to tell which side effects are definitely drug-related, which may be drug-related, and which have nothing to do with the drug. In clinical studies, up to 25 percent of people taking Rebif reported depression. However, a similar percentage of people taking a placebo also reported depression. Because depression is common among people with multiple sclerosis, it is difficult to tell whether any given case is actually caused by Rebif
(see Multiple Sclerosis and Depression for more information). However, some factors (such as the timing of the onset of depression in relationship to the medication) may suggest that Rebif may (or may not) be causing or contributing to a particular case.